Pharma Focus America

Adalvo Receives Initial EU Approval for Generic Liraglutide Prefilled Pen

Monday, June 17, 2024

Adalvo has announced the successful approval of the liraglutide prefilled pen under the EU's DCP, marking a milestone as the first generic drug approval in the region.

According to IQVIA reports, this peptide drug, a bioequivalent of the Victoza® prefilled pen and used for treating type 2 diabetes, achieved global sales exceeding $4.8 billion in 2023.

The development of liraglutide underscores Adalvo's ability to offer a comprehensive portfolio of diabetes medicines, including complex injectable peptides and small molecule oral treatments.

Adalvo is committed to providing access to high-quality, differentiated products while navigating production complexities, reinforcing its position as a trusted leader in the pharmaceutical industry.

Adalvo's portfolio of diabetes medications.

At Adalvo, our approach is resolute; we aim to outpace the competition with a winning strategy and a dedicated team.

We maintain the highest standards of excellence in all our projects and strive to deliver innovative solutions in the healthcare sector that improve the lives of patients worldwide.



Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024